It will be of interest to monitor the tumor cell-directed approach (HER2) as opposed to the myeloid-directed approaches (CCR2 and salmonella) to gain greater insight into the cell type of relevance for therapeutic STING targeting. This evidence concerns the gene STING1 and neoplasm.